The Community Focus Channel on VJHemOnc is an independent medical education platform, supported with funding from Johnson & Johnson (Gold). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
MPN Workshop of the Carolinas 2025 | The current role of fedratinib in the treatment of myelofibrosis
Alexander Coltoff, MD, Medical University of South Carolina, Charleston, SC, comments on the current role of fedratinib in the treatment of symptomatic or high-risk myelofibrosis. Dr Coltoff highlights that the agent should not be underutilized, as it is an efficacious option that has demonstrated benefits for reducing spleen size and symptom burden. As the management of side effects improves, fedratinib’s efficacy and safety profile make it a drug worth considering in both first and second-line settings. This interview took place at the 2nd Annual MPN Workshop of the Carolinas, held in Charlotte, NC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Fedratinib was the second JAK inhibitor approved for patients with higher risk myelofibrosis. And like most kind of second or third or fourth things that are approved for similar indication, I think oftentimes those drugs can kind of get left behind or get underutilized. We know from both kind of upfront trials and newly diagnosed patients, as well as in the relapsed/refractory setting for patients treated with JAK inhibitors before or ruxolitinib that fedratinib maintains good efficacy with spleen size reduction as well as symptom burden reduction, There’s been some newer studies looking at the real-world use of fedratinib and kind of more long-term data and it’s all really shown that fedratinib is a safe and effective drug for patients with symptomatic or high-risk myofibrosis...
Fedratinib was the second JAK inhibitor approved for patients with higher risk myelofibrosis. And like most kind of second or third or fourth things that are approved for similar indication, I think oftentimes those drugs can kind of get left behind or get underutilized. We know from both kind of upfront trials and newly diagnosed patients, as well as in the relapsed/refractory setting for patients treated with JAK inhibitors before or ruxolitinib that fedratinib maintains good efficacy with spleen size reduction as well as symptom burden reduction, There’s been some newer studies looking at the real-world use of fedratinib and kind of more long-term data and it’s all really shown that fedratinib is a safe and effective drug for patients with symptomatic or high-risk myofibrosis. I think as we get better at mitigating some of the side effects we see with JAK inhibitors as well, like the GI toxicity, making sure people’s thiamine levels are repleted, it really should be a drug that people reach for, both in the first and second line setting when patients need a drug that has strong spleen size improvements as well as symptom improvements.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Speaking fees: Incyte, Blueprint Medicines, Sobi; Advisory Boards: PharmaEssentia, Blueprint Medicines.
